<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00057980</url>
  </required_header>
  <id_info>
    <org_study_id>NU 02I6</org_study_id>
    <secondary_id>NU-02I6</secondary_id>
    <nct_id>NCT00057980</nct_id>
  </id_info>
  <brief_title>Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma</brief_title>
  <official_title>Phase I/II Study of Epirubicin and Celecoxib for Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor.&#xD;
      Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop&#xD;
      growing or die. Combining celecoxib with epirubicin may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of epirubicin when&#xD;
      given together with celecoxib and to see how well it works in treating patients with&#xD;
      hepatocellular carcinoma (liver cancer).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of epirubicin when administered with celecoxib in&#xD;
           patients with hepatocellular carcinoma.&#xD;
&#xD;
        -  Determine the response rate in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the 6-month and overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity profile of this regimen in these patients.&#xD;
&#xD;
        -  Determine the effects of this regimen on serum levels of vascular endothelial growth&#xD;
           factor and correlate these effects with response in these patients.&#xD;
&#xD;
        -  Correlate the expression of cyclooxygenase-2 in tumor tissue and nonmalignant liver&#xD;
           tissue with response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of epirubicin.&#xD;
&#xD;
        -  Phase I:Patients receive epirubicin IV over 20 minutes on day 1 and oral celecoxib twice&#xD;
           daily on days 1-21. Courses repeat every 21 days in the absence of disease progression&#xD;
           or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-5 patients receive escalating doses of epirubicin until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2&#xD;
      of 3 or 3 of 5 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Additional patients are accrued and treated as in phase I at the MTD of&#xD;
           epirubicin.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-52 patients (3-15 for phase I and 12-37 for phase II) will be&#xD;
      accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of epirubicin</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival at 6 months</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum vascular endothelial growth factor levels in correlation to response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cyclooxygenase-2 expression in tumor tissue and nonmalignant liver tissue in correlation to response</measure>
  </secondary_outcome>
  <enrollment type="Actual">8</enrollment>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of localized or metastatic hepatocellular carcinoma (HCC) by 1 of the&#xD;
             following:&#xD;
&#xD;
               -  Biopsy&#xD;
&#xD;
               -  Alpha-fetoprotein (AFP) measurement (greater than 400 ng/mL if hepatitis B&#xD;
                  surface antigen [HBsAg] is negative OR greater than 1,000 ng/mL if HBsAg is&#xD;
                  positive)&#xD;
&#xD;
          -  Not amenable to surgical resection or liver-directed therapy&#xD;
&#xD;
          -  Measurable or evaluable disease* NOTE: *Changes in AFP alone are not sufficient&#xD;
&#xD;
          -  Child-Pugh score A or B&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 3.0 mg/dL&#xD;
&#xD;
          -  AST no greater than 5 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF greater than 45% by MUGA or echocardiogram&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No requirement for nonsteroidal anti-inflammatory drugs (NSAIDs) except low-dose (81&#xD;
             mg) aspirin&#xD;
&#xD;
          -  No known hypersensitivity to aspirin or other NSAIDs&#xD;
&#xD;
          -  No contraindication to cyclooxygenase-2 (COX-2) inhibitor therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior therapy for HCC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Mulcahy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robert H. Lurie Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>April 7, 2003</study_first_submitted>
  <study_first_submitted_qc>April 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2003</study_first_posted>
  <disposition_first_submitted>February 18, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>February 18, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 25, 2011</disposition_first_posted>
  <last_update_submitted>June 7, 2012</last_update_submitted>
  <last_update_submitted_qc>June 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

